Evidence map›Paper›PMID 25809782›Full record

ArticleRetrovirology2015

Myocyte enhancer factor (MEF)-2 plays essential roles in T-cell transformation associated with HTLV-1 infection by stabilizing complex between Tax and CREB.

Pooja Jain, Alfonso Lavorgna, Mohit Sehgal, Linlin Gao, Rashida Ginwala, Divya Sagar, Edward W Harhaj, Zafar K Khan

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. The Molecular and Biological Function of MEF2D in Leukemia.Advances in experimental medicine and biology · 2024
    Review
  4. The Pleiotropic Effects of YBX1 on HTLV-1 Transcription.International journal of molecular sciences · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Regulation of HTLV-1 transformation.Bioscience reports · 2022
    Review
  9. Review
  10. Review
  11. Article
  12. Mechanisms of Oncogenesis by HTLV-1 Tax.Pathogens (Basel, Switzerland) · 2020
    Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Pooja Jain
Alfonso Lavorgna
Mohit Sehgal
Linlin Gao
Rashida Ginwala
Divya Sagar
Edward W Harhaj
Zafar K Khan
Drexel University · USJohns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · USSylvester Comprehensive Cancer Center · US

Funding

REGULATION OF HTLV I LTR IN IMMUNE AND NERVOUS SYSTEMSR01CA054559 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI JAIN, POOJA · 1991 to 2016
$4.8M
Mechanisms of HTLV-I Tax-mediated NF-kB activationR01CA135362 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARHAJ, EDWARD W · 2009 to 2018
$2.7M
Restoring anti-viral immunity during HTLV-associated neuroinflammatory diseaseR56AI077414 · NIAID · DREXEL UNIVERSITY · PI JAIN, POOJA · 2014 to 2014
$473k
Modeling HTLV-1 infection and cellular immune response in HLA-A2-transgenic miceR21AI093172 · NIAID · DREXEL UNIVERSITY · PI KHAN, ZAFAR K · 2011 to 2012
$425k
NCI NIH HHS R01 CA054559NCI NIH HHS R01 CA135362NIAID NIH HHS 2R56AI077414-06A1NIAID NIH HHS R21 AI093172NIAID NIH HHS R21 AI 093172-01NIAID NIH HHS R56 AI077414
6 · The paper itself

Abstract

backgroundThe exact molecular mechanisms regarding HTLV-1 Tax-mediated viral gene expression and CD4 T-cell transformation have yet to be fully delineated. Herein, utilizing virus-infected primary CD4+ T cells and the virus-producing cell line, MT-2, we describe the involvement and regulation of Myocyte enhancer factor-2 (specifically MEF-2A) during the course of HTLV-1 infection and associated disease syndrome.

resultsInhibition of MEF-2 expression by shRNA and its activity by HDAC9 led to reduced viral replication and T-cell transformation in correlation with a heightened expression of MEF-2 in ATL patients. Mechanistically, MEF-2 was recruited to the viral promoter (LTR, long terminal repeat) in the context of chromatin, and constituted Tax/CREB transcriptional complex via direct binding to the HTLV-1 LTR. Furthermore, an increase in MEF-2 expression was observed upon infection in an extent similar to CREB (known Tax-interacting transcription factor), and HATs (p300, CBP, and p/CAF). Confocal imaging confirmed MEF-2 co-localization with Tax and these proteins were also shown to interact by co-immunoprecipitation. MEF-2 stabilization of Tax/CREB complex was confirmed by a novel promoter-binding assay that highlighted the involvement of NFAT (nuclear factor of activated T cells) in this process via Tax-mediated activation of calcineurin (a calcium-dependent serine-threonine phosphatase). MEF-2-integrated signaling pathways (PI3K/Akt, NF-κB, MAPK, JAK/STAT, and TGF-β) were also activated during HTLV-1 infection of primary CD4+ T cells, possibly regulating MEF-2 activity.

conclusionsWe demonstrate the involvement of MEF-2 in Tax-mediated LTR activation, viral replication, and T-cell transformation in correlation with its heightened expression in ATL patients through direct binding to DNA within the HTLV-1 LTR.

Indexed as

Cell Transformation, ViralHost-Pathogen InteractionsCD4-Positive T-LymphocytesCells, CulturedCyclic AMP Response Element-Binding ProteinGene Products, taxHumansHuman T-lymphotropic virus 1MEF2 Transcription FactorsPromoter Regions, GeneticProtein BindingProtein MultimerizationTranscription, GeneticVirus ReplicationCREB1 protein, humanCyclic AMP Response Element-Binding ProteinGene Products, taxMEF2A protein, humanMEF2 Transcription Factorstax protein, Human T-lymphotrophic virus 1

Identifiers

PMID25809782
PMCPMC4374383
OpenAlexW2136326235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.